Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
The present review aims to examine the effect of specific drugs on long-term outcome of pulmonary arterial hypertension (PAH), to critically review the available data, and to derive useful information for daily patient care. PAH is an intrinsic disease of the pulmonary circulation with a malignant e...
Main Authors: | M. Delcroix, K. Spaas, R. Quarck |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2009-12-01
|
Series: | European Respiratory Review |
Subjects: | |
Online Access: | http://err.ersjournals.com/cgi/content/full/18/114/253 |
Similar Items
-
Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin
by: Majdy Idrees, et al.
Published: (2015-01-01) -
Pathways in pulmonary arterial hypertension: the future is here
by: Olivier Sitbon, et al.
Published: (2012-12-01) -
Advancements In pulmonary arterial hypertension treatment
by: Bains, Ashank
Published: (2018) -
Looking to the future: a new decade of pulmonary arterial hypertension therapy
by: V.V. McLaughlin
Published: (2011-12-01) -
Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension
by: Aleksandra Gąsecka, et al.
Published: (2021-03-01)